Tarlige® is the official global commercial brand name, and Delijing is its Chinese brand name developed by Daiichi‑Sankyo. It is a selective calcium channel α2‑δ ligand. It selectively binds to α2‑δ‑1 subunit of voltage‑gated calcium channels in the central nervous system, suppresses excessive release of pain‑related neurotransmitters and exerts analgesic effects.
Main Indications
Treatment of peripheral neuropathic pain in adult patients.
Clinical Research
Global multicenter phase II‑III clinical trials demonstrated that mirogabalin significantly reduces pain scores and improves sleep quality in subjects with peripheral neuropathic pain;
Dose‑finding studies confirmed obvious analgesic efficacy at 5 mg‑15 mg daily dose range;
Multicenter clinical trials conducted in Chinese patients verified efficacy and safety profiles consistent with global clinical data;
Long‑term extension studies supported sustained analgesic effect and acceptable tolerability during continuous administration.
Common Side Effects
Dizziness and somnolence are the most frequent adverse reactions;
Rare but severe risks: hypersensitivity reactions, mental‑related adverse events including suicidal ideation;
Common mild adverse reactions: headache, fatigue, nausea, vomiting, diarrhoea, peripheral oedema.
Approval Status in China
Original drug Tarlige® (Mirogabalin Besilate Tablets) was officially approved for marketing in China in 2023, with the specification of 5 mg. It is currently a prescription drug included in China’s national medical insurance catalogue.
Buy Tarlige (Mirogabalin Besilate Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
